Veterinary Rapid Syndromic Polymerase Chain Reaction (PCR) Panels Market Report 2026

The veterinary rapid syndromic polymerase chain reaction (PCR) panels market size has grown strongly in recent years. It will grow from $1.22 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to zoonotic disease outbreaks driving diagnostic demand, growth in intensive livestock farming systems, increasing companion animal healthcare expenditure, limitations of conventional culture-based diagnostic methods, rising awareness of antimicrobial resistance concerns.

The veterinary rapid syndromic polymerase chain reaction (PCR) panels market size is expected to see strong growth in the next few years. It will grow to $1.77 billion by 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to expansion of AI-assisted diagnostic interpretation tools, increasing adoption of precision veterinary medicine approaches, regulatory enforcement of antimicrobial stewardship programs, rising demand for decentralized rapid testing solutions, integration of high-throughput multiplex molecular diagnostics in veterinary workflows. Major trends in the forecast period include expansion of point-of-care rapid molecular diagnostic testing in veterinary clinics, growing adoption of syndromic pathogen detection for early disease differentiation in animals, increasing demand for multiplex PCR assays to reduce diagnostic turnaround time, rising emphasis on antibiotic stewardship-driven diagnostic decision making, expansion of centralized veterinary reference laboratory testing networks.

The growing prevalence of infectious diseases in animals is expected to propel the growth of the veterinary rapid syndromic polymerase chain reaction (PCR) panels market going forward. Infectious diseases in animals are illnesses caused by pathogenic microorganisms that invade animal hosts and can spread directly or indirectly between animals or from animals to humans. The increasing prevalence of infectious diseases in animals is driven by higher animal population density, as closer interaction between animals facilitates faster transmission and spread of pathogens. Veterinary rapid syndromic polymerase chain reaction (PCR) panels support the detection of infectious diseases in animals by enabling rapid and accurate identification of multiple pathogens simultaneously, supporting early diagnosis, timely treatment, and effective disease control. For instance, in November 2023, according to the Colorado Department of Agriculture, double the number of canine infectious respiratory disease cases were reported compared to the levels typically observed during a standard outbreak period, with similar surges simultaneously documented across at least 10 U. S. states between 2022 and 2023. Therefore, the growing prevalence of infectious diseases in animals is driving the growth of the veterinary rapid syndromic polymerase chain reaction (PCR) panels market.

The growing companion animal ownership is expected to propel the growth of the veterinary rapid syndromic polymerase chain reaction (PCR) panels market going forward. Companion animal ownership refers to the practice of individuals or households keeping domesticated animals such as dogs and cats as pets, forming bonds that include providing healthcare and veterinary services. The increasing trend of companion animal ownership is primarily driven by changing societal attitudes, as pets are increasingly considered family members, encouraging more households to adopt animals and invest in their overall well-being, including health monitoring and disease management. Veterinary rapid syndromic PCR panels enable fast and accurate multi-pathogen detection in companion animals, supporting early diagnosis, targeted treatment, and improved overall pet care. For instance, in December 2024, according to the American Veterinary Medical Association, the total population of pet dogs in the United States reached 89.7 million in 2024, rebounding from 80.1 million in 2023, reflecting an increase of approximately 9.6 million dogs within a single year. Therefore, growing companion animal ownership is driving the growth of the veterinary rapid syndromic polymerase chain reaction (PCR) panels market.

Leading companies operating in the veterinary rapid syndromic polymerase chain reaction (PCR) panels market are focusing on developing rapid, multiplex PCR-based veterinary diagnostics to improve overall animal health outcomes. Rapid, multiplex PCR-based veterinary diagnostics are molecular testing methods that rapidly detect multiple pathogens in animal samples simultaneously, enabling precise diagnosis and timely treatment decisions. For instance, in June 2025, bioMérieux, a France-based in vitro diagnostics company, launched the VETFIRE PCR kit for equine infectious respiratory disease testing. The launch utilizes the BIOFIRE SPOTFIRE System to provide rapid, point-of-care detection of seven respiratory pathogens in horses, delivering highly accurate results in under 20 minutes. It uses a simple nasopharyngeal swab that supports informed veterinary decisions for treatment, isolation, and management of suspected infections. The integration of advanced PCR technology with the SPOTFIRE platform enables quicker outbreak control, improves equine health management, and provides a scalable, user-friendly solution for routine and competition-related health screenings across the United Kingdom, Ireland, and France.

Major companies operating in the veterinary rapid syndromic polymerase chain reaction (pcr) panels market are Thermo Fisher Scientific Inc., Zoetis Inc., bioMérieux SA, IDEXX Laboratories Inc., Bio-Rad Laboratories Inc., QIAGEN N. V., Neogen Corporation, Seegene Inc., Bioneer Corporation, Molbio Diagnostics Private Limited, Sansure Biotech Inc., INDICAL BIOSCIENCE GmbH, Royal GD, GeneReach Biotechnology Corp., Ring Biotechnology Co. Ltd., Biomeme Inc., BioNote Inc., Agrolabo S. p. A., Genekam Biotechnology AG, MEGACOR Diagnostik GmbH.

North America was the largest region in the veterinary rapid syndromic polymerase chain reaction (PCR) panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary rapid syndromic polymerase chain reaction (PCR) panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the veterinary rapid syndromic polymerase chain reaction (PCR) panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The veterinary rapid syndromic polymerase chain reaction (PCR) panels market consists of sales of nucleic acid extraction kits, positive and negative control panels, multiplex assay panels, and data analysis tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.